Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Joel D. Leverson, Deepak Sampath, Andrew J. Souers, et al.
Cancer Discovery (2017) Vol. 7, Iss. 12, pp. 1376-1393
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1952
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh, Anthony Letai, Kristopher A. Sarosiek
Nature Reviews Molecular Cell Biology (2019) Vol. 20, Iss. 3, pp. 175-193
Open Access | Times Cited: 1691
BCL-2 family isoforms in apoptosis and cancer
Chloe Warren, Michelle W. Wong‐Brown, Nikola A. Bowden
Cell Death and Disease (2019) Vol. 10, Iss. 3
Open Access | Times Cited: 579
Molecular biomarkers in acute myeloid leukemia
Jeanette Prada-Arismendy, Johanna C. Arroyave-Ospina, Sarah Röthlisberger
Blood Reviews (2016) Vol. 31, Iss. 1, pp. 63-76
Closed Access | Times Cited: 277
Protein X-ray Crystallography and Drug Discovery
Laurent Maveyraud, Lionel Mourey
Molecules (2020) Vol. 25, Iss. 5, pp. 1030-1030
Open Access | Times Cited: 204
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini, Glaciano Ribeiro, Jorge Vaz Pinto Neto, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 185
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
Sheera R. Rosenbaum, Nicole A. Wilski, Andrew E. Aplin
Cancer Discovery (2021) Vol. 11, Iss. 2, pp. 266-281
Open Access | Times Cited: 135
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea, Maria L. Amaya, Paolo Strati, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4326-4335
Open Access | Times Cited: 146
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Sheau Wen Lok, James R. Whittle, François Vaillant, et al.
Cancer Discovery (2019) Vol. 9, Iss. 3, pp. 354-369
Open Access | Times Cited: 128
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Simona D’Aguanno, Donatella Del Bufalo
Cells (2020) Vol. 9, Iss. 5, pp. 1287-1287
Open Access | Times Cited: 124
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Prashanthi Ramesh, Jan Paul Medema
APOPTOSIS (2020) Vol. 25, Iss. 5-6, pp. 305-320
Open Access | Times Cited: 102
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
Frederick J. Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 68-79
Open Access | Times Cited: 101
Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression
Xiaoning Wang, Xing Qin, Ming Yan, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 92
Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity
Jordan Guillon, Coralie Petit, Bertrand Toutain, et al.
Cell Cycle (2019) Vol. 18, Iss. 19, pp. 2385-2397
Open Access | Times Cited: 86
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer
James R. Whittle, François Vaillant, Elliot Surgenor, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 4120-4134
Open Access | Times Cited: 84
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
Rachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Blood (2022) Vol. 140, Iss. 20, pp. 2127-2141
Open Access | Times Cited: 66
BH3-mimetics: recent developments in cancer therapy
Paul A. Townsend, M. V. Kozhevnikova, Olivier Cexus, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 63
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Gustavo P. Amarante‐Mendes, Aamir Rana, Tarcila Santos Datoguia, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 215-215
Open Access | Times Cited: 57
Cannabidiol regulates apoptosis and autophagy in inflammation and cancer: A review
Ze Fu, Peng-yue Zhao, Xing-Peng Yang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Álex Bataller, Guillermo Montalban‐Bravo, Alexandre Bazinet, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 3, pp. e186-e195
Closed Access | Times Cited: 11
Interpretable identification of cancer genes across biological networks via transformer-powered graph representation learning
Xiaorui Su, Pengwei Hu, Dongxu Li, et al.
Nature Biomedical Engineering (2025)
Closed Access | Times Cited: 1
Quality by Design Based Chromatography Technique Development and Validation for the Medicine Venetoclax (for Chronic Leukemia), in the Context of Impurities Including Degradation Products
Rajeshwari Dandabattina, Karunasree Merugu, Lova Gani Raju Bandaru, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 5
Open Access | Times Cited: 1
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
Xiaohong Zhao, Yuan Ren, Matthew A. Lawlor, et al.
Cancer Cell (2019) Vol. 35, Iss. 5, pp. 752-766.e9
Open Access | Times Cited: 74
Statins enhance efficacy of venetoclax in blood cancers
J. Scott Lee, Andrew W. Roberts, Dennis Juarez, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 445
Open Access | Times Cited: 73
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus, Tianyu Cai, Courtney D. DiNardo, et al.
Blood Cancer Journal (2019) Vol. 9, Iss. 2
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top